A guide to the five most-studied neurotropic peptides: cerebrolysin, semax, selank, dihexa, and pinealon. Covers mechanisms, clinical evidence, dosing, safety, and how to tell which patients may benefit.
A guide to cosmetic peptides beyond GHK-Cu, covering argireline, matrixyl, SNAP-8, and topical dermorphin analogues. Includes real trial data, dosing, and how each peptide works mechanistically.
A head-to-head clinical comparison of eight cosmetic and specialty peptides, including BPC-157 vs TB-500, IGF-1 vs IGF-1 LR3, Semax vs Selank, and GHRP-2 vs Ipamorelin, with dosing, mechanisms, safety profiles, and guidance on which to choose.
A deep-dive into davunetide (NAP/AL-108/AL-208), covering its mechanism of action, clinical trial data from PSP and AD studies, dosing, safety, and how it compares with semax, selank, cerebrolysin, and dihexa for neuroprotection.
A clinical deep-dive into dihexa, covering mechanism of action, research data, comparisons with semax, selank, cerebrolysin, and pinealon, dosing ranges used in trials, and safety considerations reviewed by HealthRX.com physicians.
A breakdown of four specialty peptides, DSIP, PT-141 (bremelanotide), kisspeptin-10, and oxytocin, covering mechanisms, dosing, evidence, and clinical use cases.
A guide to five longevity peptides, covering mechanisms, clinical and preclinical evidence, dosing data, regulatory status, and how to evaluate them safely.
A guide to FDA 503A compounded peptides covering legal status, purity standards, sterility testing, storage stability, and how they differ from unregulated research peptides.
A clinical comparison of GHRP-2 and ipamorelin covering mechanism, dosing, side-effect profiles, and how each fits into a broader peptide stack including BPC-157, TB-500, IGF-1 LR3, Semax, Selank, and Epitalon.
A clinically grounded review of HGH Fragment 176-191 (AOD 9604), covering mechanism, fat-loss data, dosing, side effects, melanotan comparisons, and myostatin inhibitor context, prepared by the HealthRX.com Editorial Team.
A guide to building an immune peptide stack. Covers thymosin alpha-1, thymulin, KPV, and larazotide with doses, trial data, safety, and how each peptide fits a specific immune target.
A guide to kisspeptin 10, covering its mechanism, dosing, evidence base, and comparison with PT-141 (bremelanotide), therapeutic oxytocin, and DSIP. Includes real trial data and prescriber guidance.
A guide to KPV and systemic immune peptides, including thymosin alpha-1, thymulin, and larazotide. Covers mechanisms, dosing evidence, regulatory status, and stacking considerations.
A deep dive into larazotide, thymosin alpha-1, KPV, and thymulin: how each peptide works, what the human trial data actually show, dosing ranges used in practice, and how clinicians are beginning to stack them.
A guide to topical peptides for skin aging, covering Matrixyl (palmitoyl pentapeptide-4), Argireline (acetyl hexapeptide-3), SNAP-8, GHK-Cu, and emerging compounds. Includes trial data, doses, and practical protocol guidance.
A clinical review of melanotan 2 risks, covering cardiovascular effects, melanoma risk, nausea, and comparisons with AOD 9604, HGH Frag 176-191, melanotan 1, and myostatin inhibitors. prepared by the HealthRX.com Editorial Team.
A guide to therapeutic oxytocin covering intranasal use, anxiety and autism research, and how it differs from PT-141 (bremelanotide), kisspeptin-10, and DSIP.
A guide to peptides for hair loss, covering GHK-Cu, PTD-DBM, AnaGain, and topical peptide stacks, with dosing, evidence, and what to expect.
A guide to peptide injection frequency covering dosing schedules for BPC-157, CJC-1295, ipamorelin, semaglutide, and more. Includes legal status, drug-test considerations, oral bioavailability, and pain management.
A guide to evaluating peptide sources, covering FDA status, compounding pharmacy standards, COA interpretation, injection safety, oral bioavailability, and drug-testing implications.
A deep dive into pinealon, the short peptide designed to support brain aging and cognitive function, plus comparisons with semax, selank, cerebrolysin, and dihexa.
A guide to PT-141 bremelanotide covering FDA-approved use for HSDD, off-label applications, dosing protocols, side effects, and comparisons with kisspeptin-10, therapeutic oxytocin, and DSIP.
Compare Semax and Selank using published human studies, separating stroke rehabilitation and anxiety research from unsupported focus, calm, and stacking claims.
A guide to SNAP-8 (acetyl octapeptide-3): how it works, what the evidence shows, how it compares to argireline, matrixyl, copper peptides, and dermorphin topical, plus dosing and safety data.
FDA sterility testing requires USP <71> sterility, endotoxin, and potency tests under 503A/503B before release, rules research chemical peptides skip entirely.
A guide to thymosin alpha-1 (Tα1): mechanism, dosing, clinical trial data, regulatory status, and how it compares to thymulin, larazotide, and KPV in immune peptide protocols.
Pioglitazone starts at 15 to 30 mg once daily, titrated every 8 to 12 weeks up to a max of 45 mg based on A1C response and fluid-retention risk.
A clinical deep-dive into micronized progesterone (Prometrium) use in patients with autoimmune conditions, covering immunomodulatory mechanisms, disease-specific guidance, dosing, and evidence boundaries.
A comparison of FDA-approved Prometrium and compounded micronized progesterone for HRT, covering bioavailability, safety data, cost, and how to choose between them.
A guide to timing Prometrium (micronized progesterone) doses across time zones, managing missed doses during travel, and preserving endometrial protection during multi-night trips and jet lag.
A week-by-week guide to PT-141 (bremelanotide) for HSDD and off-label ED. Covers dosing, side effects, and realistic timelines from the RECONNECT trial.
What happens if you take too much PT-141 (bremelanotide), how to recognize overdose signs, and the evidence-based clinical steps for managing an accidental excess dose.
A clinical guide to TRICARE coverage, prior authorization, formulary tier, step therapy, and appeal options for rapamycin (sirolimus) in 2025.
A guide to sirolimus blood-level testing, lab monitoring schedules, fertility considerations, and safety checkpoints for healthy adults aged 18 to 29 using rapamycin off-label.
A complete regulatory timeline for alprostadil (Caverject and MUSE), covering original NDA approvals, label updates, post-market safety data, and current prescribing guidance.
A complete guide to alprostadil's regulatory history across the US, EU, and beyond, covering FDA approval dates, prescribing label requirements, post-market safety data, and what clinicians need to know before prescribing Caverject or MUSE.
A comprehensive look at enclomiphene citrate's FDA regulatory history, current compounding status, international approvals, prescribing label details, and post-market safety data, with primary-source citations throughout.
Eszopiclone's label kept its 2019 boxed warning on complex sleep behaviors through 2026, with reinforced sex-based dosing but no urinary retention warning added.
A complete breakdown of every FDA label change to finasteride (Propecia, Proscar) from 2020 through 2026, including post-market safety signals, prescriber obligations, and what the updated warnings mean for patients on TRT or hair-loss therapy.
GHK-Cu has no FDA drug approval. Learn what the current regulatory field looks like, what 503A compounding rules mean for patients, what the safety data show, and where next-generation copper tripeptide research is heading.
A complete guide to ipamorelin's compounding legal status under U.S. FDA rules, including 503A/503B pharmacy requirements, the 2025 regulatory shift, safety trial data, and what clinicians should tell patients before prescribing.
Dayvigo FDA label covers 5mg/10mg dosing, hepatic impairment caps, complex sleep behavior boxed warning, and driving impairment data from 2020-2026 revisions.
A complete clinical and regulatory guide to liraglutide's patent field, FDA approval history, prescribing label, and post-market safety record, prepared by the HealthRX.com Editorial Team.
MK-677 (ibutamoren) has never received FDA or EMA approval. This article explains the full regulatory history of ibutamoren across both agencies, what the evidence shows, and the legal and clinical implications for patients and prescribers.
The FDA modafinil label warns of serious rash (SJS, TEN, DRESS), psychiatric events like mania and suicidal ideation, and cardiac caution in heart disease.
A detailed review of MOTS-c regulatory status in the United States, including FDA approval history, compounding legality, labeling requirements, and current safety data as of 2025.
A complete regulatory history of Prometrium (micronized progesterone), covering FDA approval dates, label changes, safety signals, and clinical trial evidence from PEPI to current prescribing guidance.
A review of what is and is not independently verifiable about Prometrium (micronized progesterone) label history from 2020 through 2026, including FDA regulatory context, the trials the label rests on, and how to check the current prescribing information yourself.
A comprehensive review of tretinoin topical safety signals from the FDA FAERS database, label history, post-market surveillance, and primary literature. prepared by the HealthRX.com Editorial Team.
Stopped Praluent and wondering whether to restart? This guide covers real patient experiences with alirocumab regret, what happens to LDL when you stop, and the clinical evidence on restarting.
Amlodipine response rates from trials, which used different definitions, plus edema rates by dose and how telmisartan combinations compare.
A patient-realistic guide to AndroGel results at weeks 2, 4, 8, and 12. Real timelines, real doses, and primary-source citations for every claim.
A clinical breakdown of the AndroGel non-responder profile, covering absorption failures, lab patterns, patient reviews, and the clinical steps that actually move the needle.
Thinking about stopping AndroGel or restarting after a break? This evidence-based guide covers why men quit, what happens to testosterone levels when they stop, and how to restart safely, with real patient perspectives and clinical context.
A rigorous look at AOD-9604 (HGH fragment 176-191) year-1 user outcomes synthesized from Reddit, Drugs.com, and Trustpilot reports, set against available clinical trial and regulatory data. prepared by the HealthRX.com Editorial Team.
A clinical breakdown of the BPC-157 non-responder profile: who fails to see results, what mechanisms may explain non-response, and what Reddit reports and emerging research reveal about optimizing outcomes.
Thinking about quitting BPC-157, already stopped, or wondering whether to restart? This evidence-grounded guide covers why people stop, what happens when they do, and how clinicians approach restarting cycles safely.
An evidence-checked synthesis of BPC-157 user outcomes at the one-year mark, drawing on public forum and review-platform reports alongside available preclinical and early clinical evidence. Learn what users report gaining, what they report losing, and where the science currently stands.
A clinical deep-dive into the Trulicity non-responder profile: who fails to lose weight on dulaglutide, what Reddit and Drugs.com reviews reveal, and what your doctor should try next.
Thinking about stopping dutasteride (Avodart) or restarting after a break? This guide covers regret rates, shedding timelines, how long DHT suppression lasts after discontinuation, and what the evidence says about restarting.